GlassScriptPhysician profile
Kevin Donohue
NPI 1447886627
$4,147.51
in general payments reported to CMS, 2019-2025
18 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $330 · 2022: $458 · 2023: $443 · 2024: $1,700 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,610 · Consulting Fee: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,609.57 |
| Consulting Fee | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $1,033.95 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $732.42 | 2022-2025 | Infuse, Alden Scleral Zenlens, Scoutpro Osmolarity System |
| Coopervision INC. | $432.56 | 2022-2025 | Paragon Crt, Misight Contact Lens, Onefit Contact Lens |
| Oyster Point Pharma, INC. | $328.86 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Alcon Vision LLC | $301.00 | 2025 | Clareon Panoptix Pro, Tryptyr, Rocklatan |
| Biotissue Holdings INC. | $263.16 | 2024-2025 | |
| Johnson & Johnson Vision Care, INC. | $230.44 | 2024-2025 | |
| Harrow Eye, LLC | $126.89 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $125.00 | 2021 | |
| Allergan, INC. | $124.99 | 2021 | |
| Mallinckrodt Hospital Products INC. | $105.23 | 2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $101.60 | 2022-2025 | |
| Sight Sciences, INC. | $80.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $61.10 | 2022 | |
| Dompe US, INC. | $49.09 | 2025 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $17.99 | 2023 | Syfovre |
| Abbvie INC. | $16.98 | 2025 | |
| Thea Pharma INC. | $16.07 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Donohue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.